Operability changes in patients with NSCLC after neoadjuvant chemotherapy and anti-PD-1/PD-L1

被引：0

作者：

Garitaonaindia, Yago

Baena Espinar, Javier

Aguado, Carlos

Cruz, Patricia

Lopez Castro, Rafael

Rubio, Jaime

Gomez, Ana

Lopez Martin, Ana

Traseira, Cristina

Mielgo Rubio, Xabier

Losada, Beatriz

Rogado Revuelta, Jacobo

Romano, Irene

Luis Campo-Canaveral, Jose

Gomez de Antonio, David

Falagan, Sandra

Rubio, Gustavo

Javier Montoro, Francisco

Sereno, Maria

机构：

[1] Puerta Hierro Univ Hosp, Majadahonda, Madrid, Spain

[2] Hosp Univ 12 Octubre, Madrid, Spain

[3] Hosp Clin San Carlos, Madrid, Spain

[4] Hosp Univ Cuidad Real, Ciudad Real, Spain

[5] Hosp Clin Univ Valladoli, Med Oncol Dept, Valladolid, Spain

[6] Univ Hosp Fdn Jimenez Diaz, Madrid, Spain

[7] Ramon y Cajal Univ Hosp, Madrid, Spain

[8] Hosp Severo Ochoa, Madrid, Spain

[9] Hosp Henares, Coslada, Madrid, Spain

[10] Hosp Fdn Alcorcon, Alcorcon, Madrid, Spain

[11] Hosp Univ Fuenlabrada, Madrid, Spain

[12] Infanta Leonor Univ Hosp, Madrid, Spain

[13] Infanta Sofia Univ Hosp, San Sebastian De Reyes, Madrid, Spain

[14] Puerta Hierro Univ Hosp, Madrid, Spain

[15] Infanta Sofia Univ Hosp, Dept Med Oncol, SS De Los Reyes, Madrid, Spain

[16] Infanta Sofia Univ Hosp, Dept Med Oncol, Madrid, Spain

[17] European Univ Madrid, Madrid, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8055

引用

页数：1

共 50 条

[1] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Niu, Mengke
Yi, Ming
Li, Ning
Luo, Suxia
Wu, Kongming
[J]. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
[2] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Mengke Niu
Ming Yi
Ning Li
Suxia Luo
Kongming Wu
[J]. Experimental Hematology & Oncology, 10
[3] Efficacy of anti-PD-1 antibodies in NSCLC patients with anEGFRmutation and high PD-L1 expression
Masuda, Ken
Horinouchi, Hidehito
Tanaka, Midori
Higashiyama, Ryoko
Shinno, Yuki
Sato, Jun
Matsumoto, Yuji
Okuma, Yusuke
Yoshida, Tatsuya
Goto, Yasushi
Yamamoto, Noboru
Ohe, Yuichiro
[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (01) : 245 - 251
[4] The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
Sui, Xinbing
Ma, Junhong
Han, Weidong
Wang, Xian
Fang, Yong
Li, Da
Pan, Hongming
Zhang, Li
[J]. ONCOTARGET, 2015, 6 (23) : 19393 - 19404
[5] Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1%.
Landre, Thierry
Guetz, Gaetan Des
Chouahnia, Kader
Taleb, Cherifa
Vergnenegre, Alain
Chouaid, Christos
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[6] Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
Ken Masuda
Hidehito Horinouchi
Midori Tanaka
Ryoko Higashiyama
Yuki Shinno
Jun Sato
Yuji Matsumoto
Yusuke Okuma
Tatsuya Yoshida
Yasushi Goto
Noboru Yamamoto
Yuichiro Ohe
[J]. Journal of Cancer Research and Clinical Oncology, 2021, 147 : 245 - 251
[7] Hyperresponsive Disease: A New Pattern of Response in NSCLC Patients Treated by Anti-PD-1/PD-L1
Bouchard, N.
Gauthier, M.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S462 - S462
[8] The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Wu, Dawei
Huang, Huiyao
Zhang, Minghui
Li, Ziwei
Wang, Shuhang
Yu, Yue
Fang, Yuan
Jiang, Ning
Miao, Huilei
Ma, Peiwen
Tang, Yu
Li, Ning
[J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
[9] Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis
Abdel-Rahman, Omar
[J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 101 : 75 - 85
[10] The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Dawei Wu
Huiyao Huang
Minghui Zhang
Ziwei Li
Shuhang Wang
Yue Yu
Yuan Fang
Ning Jiang
Huilei Miao
Peiwen Ma
Yu Tang
Ning Li
[J]. Journal of Hematology & Oncology, 15

← 1 2 3 4 5 →